Ray Takigiku, Ph.D.
President and CEO
Previously was Director of Discovery Core Technologies, Analytical and Bioanalytical
for Procter & Gamble Pharmaceuticals, and also Interim co-Director of the Genome
Research Institute (now Metabolic Diseases Institute) of the College of Medicine,
University of Cincinnati. Dr. Takigiku has extensive experience in leading and leveraging
multifunctional teams for developing and implementing new technologies to discover,
develop and provide technical support for pipeline and marketed drugs. He was part
of the leadership team behind the blockbuster drug Actonel®. At P&G, Dr. Takigiku
worked with global business units inside and outside of healthcare, testing and
developing new models of innovation.
In addition to being a Director at Bexion, Dr. Takigiku serves on a number of Boards,
including Health Source of Ohio. Dr. Takigiku received his undergraduate degrees
from the University of Colorado, and Ph.D. from Indiana University.
Michael Gazda, Ph.D.
Previously was Section Head, Research and Development, for Procter & Gamble Pharmaceuticals
and Personal Health Care business units. Dr. Gazdaâ€™s experience includes pre-formulation,
formulation and drug delivery, new technology development, and drug product scale-up
and manufacturing, in the areas of pharmaceuticals, OTC products, and supplements.
He has led full project teams in the IND phase of drug development, and has also
done consulting in the areas of early phase drug development and translational research.
Dr. Gazda received his B.S. in Chemistry from Lawrence Technological University,
and his Ph.D. in Analytical Chemistry from Purdue University.
Sandra Nelson, Ph.D.
Previously was the Chief Technology Officer for Molecular Diagnostics Laboratories
(MDL). Prior to joining MDL, she established and led an automated high throughput
screening (HTS) HTS lab with image analysis capability at the University of Cincinnati
(UC), as a key capability of the UC Drug Discovery Center. Her work experience includes
18 years at Procter & Gamble Pharmaceuticals where she led the HTS team and the
automated compound repository, and held leadership roles in the development of several
health care products.
Dr. Nelson is currently a reviewer for two scientific journals, has been a member
of several NIH grant review panels and was chairperson for the Society for Biomolecular
Screening. She received her Ph.D. in Biochemistry from the University of North Carolina,
Chapel Hill, and a B.S. in Biochemistry from Iowa State University.
Tom Wei, Ph.D.
Previously was the Associate Director of the Research and Development and Quality
Control labs at Coldstream Laboratories. His experience includes the development
and validation of analytical methods for drug substances and products under cGMP
and ICH guidelines.
Dr. Wei received his Ph.D. (1999) in Plant & Soil Sciences (Natural Product Chemistry)
from the University of Kentucky with post-doctoral work in biological activities,
including anticancer and antileukemic activities of plant natural products.
Christy Rothwell, J.D., Ph.D.
Vice President, Intellectual Property
Dr. Rothwell has expertise in intellectual property, including strategy, patent
prosecution and enforcement, portfolio management, transactional agreements, and
due diligence. She has served both as outside counsel and in-house counsel to pharmaceutical
and life science companies, and universities. Dr. Rothwell has also provided strategic
counseling with regard to patent, regulatory, and competitive landscapes throughout
the process of global branded and generic pharmaceutical and biologic product development.
Her doctoral work was in tumor cell biology, and metastasis.
Dr. Rothwell received her J.D. from Duquesne University, Ph.D. in Biomedical Science-Tumor
Biology from Georgetown University, and B.S. in Chemistry and Medical Technology
from Georgetown College.
Kevin Xu, M.D., Ph.D., M.B.A.
Vice President, Global Operations
Previously was Senior Research Scientist at Procter & Gamble Pharmaceuticals. Practiced
in clinical medicine, surgery, biomedical and drug research, Dr. Xu co-founded Bexion
with Dr. Ray Takigiku and Dr. Xiaoyang Qi.
Dr. Xu received his medical training from the Medical College of Peking University,
China, and his Ph.D. (Tumor Biology) from the Mayo Graduate School of the Mayo Clinic,
Minnesota. He has an M.B.A. from Xavier University, Ohio.
Margaret van Gilse, M.B.A.
Vice President, Business Development
Previously was Vice President, Business Development for PrimeDP, a global drug development
consulting company, where she supported life science projects and product registrations,
and managed local and regional government and business relations. Ms. van Gilse
has over 25 years of business development, strategic planning and fund raising experience
with entrepreneurial companies in multiple healthcare segments.
Ms. van Gilse has served on the Northern Kentucky American Cancer Society and Gateway
Community and Technical School Boards. Currently she is a member of the Covington
Business Council Board and co-chairs the KY CEOs against Cancer initiative. She
received her undergraduate degree in Biology and Chemistry from Thomas More College
and her MBA from Xavier University.